Stockscreener 앱 받기
9.71
3.08%
0.29
시간 외 거래:
9.80
0.09
+0.93%
전일 마감가:
$9.42
열려 있는:
$9.66
하루 거래량:
609.27K
Relative Volume:
0.81
시가총액:
$490.49M
수익:
$89.04M
순이익/손실:
$-241.08M
주가수익비율:
-1.846
EPS:
-5.26
순현금흐름:
$-194.72M
1주 성능:
+8.73%
1개월 성능:
+17.13%
6개월 성능:
+55.36%
1년 성능:
-14.67%
1일 변동 폭
$9.56
$9.97
1주일 범위
$8.75
$9.97
52주 변동 폭
$5.035
$13.48
Regenxbio Inc Stock (RGNX) Company Profile
명칭
Regenxbio Inc
전화
240-552-8181
주소
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
RGNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
9.71 | 475.84M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-11 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-02-07 | 재개 | Raymond James | Outperform |
| 2024-11-15 | 재개 | Morgan Stanley | Overweight |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-06-07 | 개시 | Goldman | Buy |
| 2024-03-11 | 개시 | H.C. Wainwright | Buy |
| 2024-03-08 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | 재개 | Raymond James | Outperform |
| 2023-11-01 | 개시 | Stifel | Buy |
| 2023-06-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-15 | 개시 | Wedbush | Neutral |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-01-06 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | 재확인 | Chardan Capital Markets | Buy |
| 2019-06-14 | 재개 | Raymond James | Outperform |
| 2019-06-05 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-25 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-02-05 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | 재확인 | Chardan Capital Markets | Buy |
| 2018-11-08 | 재확인 | BofA/Merrill | Neutral |
| 2018-08-08 | 재확인 | Chardan Capital Markets | Buy |
| 2018-07-23 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | 재확인 | Chardan Capital Markets | Buy |
| 2018-05-09 | 재확인 | Barclays | Overweight |
| 2018-04-09 | 재확인 | Chardan Capital Markets | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-02-13 | 개시 | Mizuho | Neutral |
| 2017-11-09 | 재개 | Morgan Stanley | Overweight |
모두보기
Regenxbio Inc 주식(RGNX)의 최신 뉴스
REGENXBIO Inc. recovery potential after sell offAnalyst Downgrade & Safe Entry Zone Identification - Newser
Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome (NASDAQ:RGNX) - Seeking Alpha
Can REGENXBIO Inc. expand into new markets2025 Earnings Surprises & Advanced Technical Signal Analysis - خودرو بانک
Top chart patterns to watch in REGENXBIO Inc.Weekly Investment Recap & AI Optimized Trading Strategy Guides - Newser
Is REGENXBIO Inc.’s ROIC above industry averageTreasury Yields & Real-Time Stock Movement Alerts - خودرو بانک
Goldman Sachs reiterates Neutral rating on Regenxbio stock at $14 target - Investing.com Australia
REGENXBIO reports positive one-year data for MPS II gene therapy - Investing.com Nigeria
Should value investors consider REGENXBIO Inc.2025 Stock Rankings & Daily Stock Trend Reports - خودرو بانک
Can REGENXBIO Inc. expand its profit marginsWeekly Risk Report & Free Reliable Trade Execution Plans - خودرو بانک
Regenxbio stock maintains Outperform rating at Raymond James on MPS II data - Investing.com Nigeria
Regenxbio stock maintains Outperform rating at Raymond James on MPS II data By Investing.com - Investing.com South Africa
Will REGENXBIO Inc. bounce back from current supportQuarterly Profit Summary & Safe Investment Capital Preservation Plans - Newser
Risk adjusted return profile for REGENXBIO Inc. analyzed2025 Price Targets & Low Risk Entry Point Tips - Newser
Regenxbio Unveils 12-Month Data For Gene Therapy Soon After FDA Delays Review Date - Benzinga
Long term hold vs stop loss in REGENXBIO Inc.Fed Meeting & Daily Oversold Bounce Ideas - Newser
Regenxbio trumpets one-year data for Hunter syndrome gene therapy after FDA extended its review - Endpoints News
REGENXBIO reports positive data from Hunter syndrome (RGNX) - Seeking Alpha
Navigating Biotech Innovation Amid Sector Volatility: High-Conviction Opportunities in 2025 - AInvest
Sector Update: Health Care Stocks Mixed Pre-Bell Friday - MarketScreener
RGX-121 and the Path to Accelerated FDA Approval: A Strategic Inflection Point for REGENXBIO - AInvest
Can machine learning forecast REGENXBIO Inc. recoveryWeekly Trend Summary & Consistent Growth Equity Picks - Newser
82% Brain Disease Marker Drop: REGENXBIO's One-Time Hunter Syndrome Treatment Shows Promise in Pivotal Trial - Stock Titan
What MACD signals say about REGENXBIO Inc.Trend Reversal & Free Safe Capital Growth Stock Tips - Newser
Should you wait for a breakout in REGENXBIO Inc.2025 Fundamental Recap & High Accuracy Investment Signals - Newser
Multi factor analysis applied to REGENXBIO Inc.July 2025 Rallies & Comprehensive Market Scan Reports - Newser
How to monitor REGENXBIO Inc. with trend dashboardsQuarterly Earnings Report & Safe Capital Growth Tips - Newser
Analyzing REGENXBIO Inc. with multi timeframe charts2025 Buyback Activity & Safe Capital Growth Stock Tips - Newser
News impact scoring models applied to REGENXBIO Inc.July 2025 Review & Long Hold Capital Preservation Plans - Newser
Can trapped investors hope for a rebound in REGENXBIO Inc.2025 Trading Volume Trends & High Accuracy Swing Entry Alerts - Newser
What high frequency data says about REGENXBIO Inc.2025 Technical Overview & Reliable Volume Spike Alerts - Newser
What is REGENXBIO Inc. s debt to equity ratioTrade Volume Summary & Real-Time Volume Triggers - خودرو بانک
Candlestick signals on REGENXBIO Inc. stock todayJuly 2025 Pullbacks & AI Forecasted Entry and Exit Points - Newser
Order Flow Trends Show Accumulation in REGENXBIO Inc.Market Performance Report & Community Consensus Picks - beatles.ru
What’s next for REGENXBIO Inc. stock price2025 AllTime Highs & Safe Capital Growth Trade Ideas - Newser
What recovery options are there for REGENXBIO Inc.July 2025 Outlook & Daily Entry Point Alerts - Newser
REGENXBIO Inc. Stocks Attracting Dip Buyers getLinesFromResByArray error: size == 0 - thegnnews.com
Strategies to average down on REGENXBIO Inc.July 2025 Recap & Free Daily Entry Point Trade Alerts - Newser
Will REGENXBIO Inc. stock go up in YEARJuly 2025 Sector Moves & Stepwise Trade Signal Implementation - خودرو بانک
Signal strength of REGENXBIO Inc. stock in tech scannersPortfolio Value Summary & Low Risk High Reward Trade Ideas - Newser
Trend analysis for REGENXBIO Inc. this weekMarket Volume Report & Daily Entry Point Trade Alerts - Newser
Can REGENXBIO Inc. be recession proofJuly 2025 Retail & Weekly High Return Forecasts - خودرو بانک
How institutional ownership impacts REGENXBIO Inc. stockQuarterly Market Summary & Free High Return Stock Watch Alerts - Newser
Applying Wyckoff theory to REGENXBIO Inc. stockM&A Rumor & Pattern Based Trade Signal System - Newser
Has REGENXBIO Inc. found a price floorRisk Management & Free High Accuracy Swing Entry Alerts - Newser
Is this a good reentry point in REGENXBIO Inc.Weekly Stock Summary & Expert Verified Movement Alerts - Newser
Regenxbio Inc (RGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):